Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about XTLB, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bicifadine | Chronic Peripheral Neuropathy Pain in Diabetics | Phase 2 · NCT00597649 | Terminated |
| XTL 6865 | Hepatitis C | Phase 1 · NCT00300807 | Unknown |
| XTL-2125 | Chronic Hepatitis C Virus Infection | Phase 1 · NCT00255359 | Withdrawn |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
XTLB holds $76,000 in cash and short-term investments and burns about $256,250/quarter from operations, an estimated runway of 0.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XTLB files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XTLB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →